Serum insulin-like growth factor-1 and nitric oxide levels in parkinson's disease

Mediators of Inflammation

Volumn 2009, Issue , 2009, Pages

  Tuncel, Deniz ^a   Inanc Tolun, Fatma ^a   Toru, Ismail ^a  

^a KAHRAMANMARAS SUTCU IMAM UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; NITRIC OXIDE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADAPTATION; AGED; ARTICLE; CLINICAL ARTICLE; CONTROL GROUP; CONTROLLED STUDY; FEMALE; HUMAN; INSULIN BLOOD LEVEL; MALE; NERVE DEGENERATION; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTECTION; BLOOD; METABOLISM; MIDDLE AGED;

AGED; FEMALE; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; NITRIC OXIDE; PARKINSON DISEASE;

EID: 63849300978     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2009/132464     Document Type: Article

References (23)

1. Abou-Sleiman P. M., Muqit M. M. K., Wood N. W., Expanding insights of mitochondrial dysfunction in Parkinsons disease Nature Reviews Neuroscience 2006 7 3 207 219
2. Nunes C., Almeida L., Laranjinha J., Synergistic inhibition of respiration in brain mitochondria by nitric oxide and dihydroxyphenylacetic acid (DOPAC): implications for Parkinsons disease Neurochemistry International 2005 47 3 173 182
3. Heales S. J. R., Lam A. A. J., Duncan A. J., Land J. M., Neurodegeneration or neuroprotection: the pivotal role of astrocytes Neurochemical Research 2004 29 3 513 519
4. Kavya R., Saluja R., Singh S., Dikshit M., Nitric oxide synthase regulation and diversity: implications in Parkinsons disease Nitric Oxide 2006 15 4 280 294
5. Brne B., Nitric oxide: NO apoptosis or turning it ON? Cell Death Differentiation 2003 10 8 864 869
6. Singh S., Dikshit M., Apoptotic neuronal death in Parkinsons disease: involvement of nitric oxide Brain Research Reviews 2007 54 2 233 250
7. Pirttil T., Vanhatalo S., Turpeinen U., Riikonen R., Cerebrospinal fluid insulin-like growth factor-1, insulin growth factor binding protein-2 or nitric oxide are not increased in MS or ALS Acta Neurologica Scandinavica 2004 109 5 337 341
8. Busiguina S., Fernandez A. M., Barrios V., Neurodegeneration is associated to changes in serum insulin-like growth factors Neurobiology of Disease 2000 7 6 657 665
9. Trejo J. L., Carro E., Garcia-Galloway E., Torres-Aleman I., Role of insulin-like growth factor I signaling in neurodegenerative diseases Journal of Molecular Medicine 2004 82 3 156 162
10. Offen D., Shtaif B., Hadad D., Weizman A., Melamed E., Gil-Ad I., Protective effect of insulin-like-growth-factor-1 against dopamine-induced neurotoxicity in human and rodent neuronal cultures: possible implications for Parkinsons disease Neuroscience Letters 2001 316 3 129 132
11. Goetz C. G., Poewe W., Rascol O., Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. The Movement Disorder Society Task Force on rating scales for Parkinsons disease Movement Disorders 2004 19 9 1020 1028
12. Cortas N. K., Wakid N. W., Determination of inorganic nitrate in serum and urine by a kinetic cadmium-reduction method Clinical Chemistry 1990 36 8 1440 1443
13. Manukhina E. B., Mashina S. Yu., Smirin B. V., Role of nitric oxide in adaptation to hypoxia and adaptive defense Physiological Research 2000 49 1 89 97
14. Sanchez-Ramos J. R., Overvik E., Ames B. N., A marker of oxyradical-mediated DNA damage. (8-hydroxy- 2′ deoxyguanosine) is increased in nigro striatum of Parkinsons disease brain Neurodegen 1994 3 197 204
15. Molina J. A., Jimnez-Jimnez F. J., Navarro J. A., Cerebrospinal fluid nitrate levels in patients with Parkinsons disease Acta Neurologica Scandinavica 1996 93 2-3 123 126
16. Shukla R., Rajani M., Srivastava N., Barthwal M. K., Dikshit M., Nitrite and malondialdehyde content in cerebrospinal fluid of patients with Parkinsons disease International Journal of Neuroscience 2006 116 12 1391 1402
17. Kalra J., Rajput A. H., Mantha S. V., Chaudhary A. K., Prasad K., Oxygen free radical producing activity of polymorphonuclear leukocytes in patients with Parkinsons disease Molecular and Cellular Biochemistry 1992 112 2 181 186
18. Qureshi G. A., Baig S., Bednar I., Sodersten P., Forsberg G., Siden A., Increased cerebrospinal fluid concentration of nitrite ire Parkinsons disease NeuroReport 1995 6 12 1642 1644
19. Kuiper M. A., Visser J. J., Bergmans P. L. M., Scheltens P., Wolters E. C., Decreased cerebrospinal fluid nitrate levels in Parkinsons disease, Alzheimers disease and multiple system atrophy patients Journal of the Neurological Sciences 1994 121 1 46 49
20. Huski J., Paperniku A., Husi A., Alendar F., Mulabegovi N., Significantly reduced salivary nitric oxide synthesis in patients with Parkinsons disease Bosnian Journal of Basic Medical Sciences 2005 5 3 86 89
21. Carro E., Torres-Aleman I., The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimers disease European Journal of Pharmacology 2004 490 13 127 133
22. Guan J., Krishnamurthi R., Waldvogel H. J., Faull R. L. M., Clark R., Gluckman P., N-terminal tripeptide of IGF-1 (GPE) prevents the loss of TH positive neurons after 6-OHDA induced nigral lesion in rats Brain Research 2000 859 2 286 292
23. Krishnamurthi R., Stott S., Maingay M., N-terminal tripeptide of IGF-I improves functional deficits after 6-OHDA lesion in rats NeuroReport 2004 15 10 1601 1604